Literature DB >> 6178690

Pathogenesis of herpes simplex labialis: correlation of vesicle fluid interferon with lesion age and virus titer.

S L Spruance, J A Green, G Chiu, T J Yeh, G Wenerstrom, J C Overall.   

Abstract

Of 51 patients with herpes simplex labialis, 50 had detectable interferon (IFN) in samples of lesion vesicle fluid. The median titer of vesicle fluid IFN was 8,200 U. and the range of values was 400 to 63,600 U. The amount of vesicle fluid IFN was correlated with lesion age (r = 0.32, P = 0.024) and vesicle fluid virus titer (r = 0.59, P = 0.00004), but not with the clinical severity of the disease. The presence of vesicle fluid IFN (1,500 to 28,600 U) in 15 lesions less than 12 h old emphasizes the need for early treatment in studies of antiviral agents for herpes simplex labialis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6178690      PMCID: PMC551415          DOI: 10.1128/iai.36.3.907-910.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

1.  Herpesvirus hominis infection in newborn mice. I. An experimental model and therapy with iododeoxyuridine.

Authors:  E R Kern; J C Overall; L A Glasgow
Journal:  J Infect Dis       Date:  1973-09       Impact factor: 5.226

2.  Interferon, antibody, and other host factors in herpes zoster.

Authors:  D A Stevens; T C Merigan
Journal:  J Clin Invest       Date:  1972-05       Impact factor: 14.808

3.  Treatment of recurrent herpes simplex labialis with levamisole.

Authors:  S L Spruance; G G Krueger; J MacCalman; J C Overall; M R Klauber
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

4.  Ineffectiveness of topical adenine arabinoside 5'-monophosphate in the treatment of recurrent herpes simplex labialis.

Authors:  S L Spruance; C S Crumpacker; H Haines; C Bader; K Mehr; J MacCalman; L E Schnipper; M R Klauber; J C Overall
Journal:  N Engl J Med       Date:  1979-05-24       Impact factor: 91.245

5.  Topical ether and herpes simplex labialis.

Authors:  M E Guinan; J MacCalman; E R Kern; J C Overall; S L Spruance
Journal:  JAMA       Date:  1980-03-14       Impact factor: 56.272

6.  Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root.

Authors:  G J Pazin; J A Armstrong; M T Lam; G C Tarr; P J Jannetta; M Ho
Journal:  N Engl J Med       Date:  1979-08-02       Impact factor: 91.245

7.  The natural history of recurrent herpes simplex labialis: implications for antiviral therapy.

Authors:  S L Spruance; J C Overall; E R Kern; G G Krueger; V Pliam; W Miller
Journal:  N Engl J Med       Date:  1977-07-14       Impact factor: 91.245

8.  Sensitivity of herpes simplex virus types 1 and 2 to three preparations of human interferon.

Authors:  J C Overall; T J Yeh; E R Kern
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

9.  Rapid, quantitative, semiautomated assay for virus-induced and immune human interferons.

Authors:  J A Green; T J Yeh; J C Overall
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

10.  Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses.

Authors:  I Gresser; M G Tovey; C Maury; M T Bandu
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

View more
  7 in total

1.  Independent and cooperative antiviral actions of beta interferon and gamma interferon against herpes simplex virus replication in primary human fibroblasts.

Authors:  Tao Peng; Jia Zhu; Yon Hwangbo; Lawrence Corey; Roger E Bumgarner
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

Review 2.  Novel composite efficacy measure to demonstrate the rationale and efficacy of combination antiviral-anti-inflammatory treatment for recurrent herpes simplex labialis.

Authors:  Christopher M Hull; Myron J Levin; Stephen K Tyring; Spotswood L Spruance
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

3.  Therapy of genital herpes with topically applied interferon.

Authors:  L J Eron; C Toy; B Salsitz; R R Scheer; D L Wood; P I Nadler
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

4.  Alpha and gamma interferons inhibit herpes simplex virus type 1 infection and spread in epidermal cells after axonal transmission.

Authors:  Z Mikloska; A L Cunningham
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte responses.

Authors:  J W Torseth; G H Cohen; R J Eisenberg; P W Berman; L A Lasky; C P Cerini; C J Heilman; S Kerwar; T C Merigan
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

6.  Tissue-resident T cell-derived cytokines eliminate herpes simplex virus-2-infected cells.

Authors:  Pavitra Roychoudhury; David A Swan; Elizabeth Duke; Lawrence Corey; Jia Zhu; Veronica Davé; Laura Richert Spuhler; Jennifer M Lund; Martin Prlic; Joshua T Schiffer
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

7.  Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract.

Authors:  Joshua T Schiffer; David Swan; Ramzi Al Sallaq; Amalia Magaret; Christine Johnston; Karen E Mark; Stacy Selke; Negusse Ocbamichael; Steve Kuntz; Jia Zhu; Barry Robinson; Meei-Li Huang; Keith R Jerome; Anna Wald; Lawrence Corey
Journal:  Elife       Date:  2013-04-16       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.